Decheng Capital Management Iii (Cayman), LLC I Mab Call Options Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
41Shares Held
15.8MCall Options Held
3KPut Options Held
1.9K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$7.53 Million0.3% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.38MShares$1.5 Million0.07% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny577KShares$628,4940.0% of portfolio
-
Two Sigma Investments, LP New York, NY478KShares$521,5010.0% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$338,4430.14% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $90.6M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...